The relationship between the human leukocyte antigen system and Crimean-Congo hemorrhagic fever in the Turkish population

International Journal of Infectious Diseases

Volumn 17, Issue 11, 2013, Pages e1038-e1041

  Akinci, Esragül ^a   Bodur, Hürrem ^a   Muşabak, Uǧur ^b   Saǧkan, Rahşan I ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; Genetic factors; HLA

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA CW ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENETIC RISK; HLA SYSTEM; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC);

CRIMEAN-CONGO HEMORRHAGIC FEVER; GENETIC FACTORS; HLA;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; TURKEY;

EID: 84885383944     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.06.005     Document Type: Article

References (34)

1. Blackwell J.M., Jamieson S.E., Burgner D. HLA and infectious diseases. Clin Microbiol Rev 2009, 22:370-385.
2. Singh N., Agrawal S., Rastogi A.K. Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg Infect Dis 1997, 3:41-49.
3. Gough S.C., Simmonds M.J. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics 2007, 8:453-465.
4. Yilmaz G.R., Buzgan T., Irmak H., Safran A., Uzun R., Cevik M.A., et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 2009, 13:380-386.
5. Jamil B., Hasan R.S., Sarwari A.R., Burton J., Hewson R., Clegg C. Crimean-Congo hemorrhagic fever: experience at a tertiary care hospital in Karachi, Pakistan. Trans R Soc Trop Med Hyg 2005, 99:577-584.
6. Bodur H., Akinci E., Ascioglu S., Öngürü P., Uyar Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis 2012, 18:640-642.
7. Elaldi N., Bodur H., Ascioglu S., Celikbas A., Ozkurt Z., Vahaboglu H., et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect 2009, 58:238-244.
8. Leblebicioglu H., Bodur H., Dokuzoguz B., Elaldi N., Güner R., Koksal I., et al. Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2012, 12:805-811.
9. Karti S.S., Odabasi Z., Korten V., Yilmaz M., Sonmez M., Caylan R., et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004, 10:1379-1384.
10. Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents 2010, 36(Suppl 1):S43-S46.
11. Andersson I., Karlberg H., Mousavi-Jazi M., Martínez-Sobrido L., Weber F., Mirazimi A. Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J Med Virol 2008, 80:1397-1404.
12. Connolly-Andersen A.M., Moll G., Andersson C., Akerström S., Karlberg H., Douagi I., et al. Crimean-Congo hemorrhagic fever virus activates endothelial cells. J Virol 2011, 85:7766-7774.
13. Yapar M., Aydogan H., Pahsa A., Besirbellioglu B.A., Bodur H., Basustaoglu A.C., et al. Rapid and quantitative detection of Crimean-Congo hemorrhagic fever virus by one-step real-time reverse transcriptase-PCR. Jpn J Infect Dis 2005, 58:358-362.
14. Cevik M.A., Erbay A., Bodur H., Gülderen E., Baştuǧ A., Kubar A., et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2008, 12:374-379.
15. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., et al. Three dimensional structure of the human class II histocompatibility antigen HLADR1. Nature 1993, 364:33-39.
16. Rani R., Fernandez-Vina M.A., Zaheer S.A., Beena K.R., Stastny P. Study of HLA class II alleles by PCR oligotyping in leprosy patients from North India. Tissue Antigens 1993, 42:133-137.
17. Hill A.V., Elvin J., Wills A.C., Aidoo M., Allsopp C.E.M., Gotch F.M., et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992, 360:434-439.
18. Hill A.V., Allsopp C.E., Kwiatkowski D., Anstey N.M., Twumasi P., Rowe P.A., et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 1991, 352:595-600.
19. Faghiri Z., Tabei S.Z., Taheri F. Study of the association of HLA class I antigens with kala azar. Hum Hered 1995, 45:258-261.
20. Tomiyama H., Miwa K., Shiga H., Moore Y.I., Oka S., Iwamoto A., et al. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J Immunol 1997, 158:5026-5034.
21. Peano G., Menardi G., Ponzetto A., Fenoglio L.M. HLADR5 antigen. A genetic factor influencing the outcome of hepatitis C virus infection?. Arch Intern Med 1994, 154:2733-2736.
22. Lee S.P., Morgan S., Skinner J., Thomas W.A., Jones S.R., Sutton J., et al. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol 1995, 25:102-110.
23. Chu R.H., Ma L.X., Wang G., Shao L.H. Influence of HLA-DRB1 alleles ad HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J Gastroenterol 2005, 11:4753-4757.
24. Stephens H.A. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol 2010, 338:99-114.
25. Korva M., Saksida A., Kunilo S., Vidan Jeras B., Avsic-Zupanc T. HLA-associated hemorrhagic fever with renal syndrome disease progression in Slovenian patients. Clin Vaccine Immunol 2011, 18:1435-1440.
26. Mustonen J., Partanen J., Kanerva M., Pietilä K., Vapalahti O., Pasternack A., et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol 1998, 47:277-279.
27. Mäkelä S., Mustonen J., Ala-Houhala I., Hurme M., Partanen J., Vapalahti O., et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha (-308) G/A polymorphism. J Infect Dis 2002, 186:843-846.
28. Bente D.A., Alimonti J.B., Shieh W.J., Camus G., Ströher U., Zaki S., et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 2010, 84:11089-11100.
29. Saksida A., Duh D., Wraber B., Dedushaj I., Ahmeti S., Avsic-Zupanc T. Interacting roles of immune mechanisms and viral load in the pathogenesis of Crimean-Congo hemorrhagic fever. Clin Vaccine Immunol 2010, 17:1086-1093.
30. Weber F., Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus: an emerging and neglected viral zoonosis. Cytokine Growth Factor Rev 2008, 19:395-404.
31. Bakir M., Ugurlu M., Dokuzoguz B., Bodur H., Tasyaran M.A., Vahaboglu H Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005, 54:385-389. Turkish CCHF Study Group.
32. Hatipoglu C.A., Bulut C., Yetkin M.A., Ertem G.T., Erdinc F.S., Kilic E.K., et al. Evaluation of clinical and laboratory predictors of fatality in patients with Crimean-Congo haemorrhagic fever in a tertiary care hospital in Turkey. Scand J Infect Dis 2010, 42:516-521.
33. Ozkurt Z., Kiki I., Erol S., Erdem F., Yilmaz N., Parlak M., et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006, 52:207-215.
34. Cevik M.A., Erbay A., Bodur H., Eren S.S., Akinci E., Sener K., et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis 2007, 45:e96-e100.